HER2 Antibody (DA164)
HER2 Antibody (DA164)
Recombinant monoclonal mouse antibody
Description
Her2 is a member of human epidermal growth factor family and encodes for a receptor tyrosine kinase involved in signal paths of growth factors. Overexpression of Her2 gene is associated with development of various carcinomas including breast, ovary, colon, prostate, bladder and lung. Her2 plays an important role in diagnosis and therapy of breast cancer as it is overexpressed in 15 - 30 % of all cases, which has been shown to be an indicator for poor prognosis with more aggressive progression of disease and decreased overall survival. 1-7
References
1. Ménard S, Pupa SM, Campiglio M and Tagliabue E (2003): Biologic and therapeutic role of HER2 in cancer. Oncogene. 22: 6570-6578.
2. Ellis CM, Dyson MJ, Stephenson TJ and Matlby EL (2005): HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 58: 710-714.
3. Muthuswamy SK, Gilman M and Brugge JS (1999): Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 19(10): 6845-6857.
4. Klapper LN, Waterman H, Sela M and Yarden Y (2000): Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60(13): 3384-3388.
5. Ricardo SA, Milanezi F, Carvalho ST et al. (2007): HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 60(9):1001-5.
6. Hudziak RM, Schlessinger J and Ullrich A (1987): Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 84(20):7159-63.
7. Kokai Y, Cohen JA, Drebin JA and Greene MI (1987): Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A. 84(23):8498-501.
2. Ellis CM, Dyson MJ, Stephenson TJ and Matlby EL (2005): HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 58: 710-714.
3. Muthuswamy SK, Gilman M and Brugge JS (1999): Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 19(10): 6845-6857.
4. Klapper LN, Waterman H, Sela M and Yarden Y (2000): Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60(13): 3384-3388.
5. Ricardo SA, Milanezi F, Carvalho ST et al. (2007): HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 60(9):1001-5.
6. Hudziak RM, Schlessinger J and Ullrich A (1987): Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 84(20):7159-63.
7. Kokai Y, Cohen JA, Drebin JA and Greene MI (1987): Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A. 84(23):8498-501.
Specifications
Application:
IHC (FFPE)
Host:
Mouse
Subclass:
IgG1/κ
Immunogen:
Synthetic peptide from human Her2
Cellular location:
Cell membrane
Control:
Breast Cancer
Order information
| DMRD0203 | Concentrate | IVD(R) |
| DMRD0203 | 10 ml Ready to use | IVD(R) |
| DMRD0203 | 6 ml Ready to use | IVD(R) |
| DMRD0203 | 3 ml Ready to use | IVD(R) |
